文献速递眼底病与葡萄膜炎神经眼科

眼内炎症与恶性肿瘤相关血-视网膜屏障破坏的机制

Mechanisms of blood-retinal barrier disruption related to intraocular inflammation and malignancy.
PubMed 文献 · Prog Retin Eye Res · 2024-01-17

本文综述血-视网膜屏障(BRB)破坏在中间型、后型及全葡萄膜炎中常见,导致视网膜渗漏和黄斑水肿引起视力下降;而前葡萄膜炎或眼内淋巴瘤患者较少见。化疗新药(阿糖胞苷、免疫检查点抑制剂、BRAF抑制剂、EGFR抑制剂、双特异性抗EGFR抑制剂、MET受体抑制剂及布鲁顿酪氨酸激酶抑制剂)也可引起不同类型葡萄膜炎和BRB破坏。恶性肿瘤本身(尤其乳腺癌、肺癌和胃肠道癌)可致葡萄膜炎,免疫抑制和/或化疗可致感染,均增加BRB破坏原因鉴别难度。文章讨论BRB破坏的病理生理、评估方法及为何某些类型眼内炎症和恶性肿瘤导致BRB破坏而另一些不导致,理解此有助于患者分诊管理及未来治疗策略设计。

要点

  • BRB破坏常见于中间型、后型和全葡萄膜炎,导致视网膜渗漏和黄斑水肿引起视力下降。
  • 多种化疗新药可导致不同类型葡萄膜炎和BRB破坏。
  • 恶性肿瘤本身及治疗相关免疫抑制均可引起BRB破坏,临床鉴别困难。

核心结论

  • 理解眼内炎症和恶性肿瘤导致BRB破坏的病理生理机制可能有助于患者分诊和管理,以及设计未来治疗方法。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • BRB破坏是中间型、后型和全葡萄膜炎的常见伴随表现,导致视网膜渗漏和黄斑水肿引起视力下降。
  • BRB破坏在前葡萄膜炎或眼内淋巴瘤患者中远不常见,后者可能有明显眼内炎症体征。
  • 化疗新药(阿糖胞苷、免疫检查点抑制剂、BRAF抑制剂、EGFR抑制剂、双特异性抗EGFR抑制剂、MET受体抑制剂和布鲁顿酪氨酸激酶抑制剂)可引起不同类型葡萄膜炎和BRB破坏。
  • 恶性肿瘤本身可致葡萄膜炎,尤其来自乳腺癌、肺癌和胃肠道癌。
  • 恶性肿瘤和/或化疗所致免疫抑制可导致感染,也可引起BRB破坏和眼内感染。

关键数值与推荐

  • 原文未报告具体标准或数值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Blood-retinal barrier (BRB) disruption is a common accompaniment of intermediate, posterior and panuveitis causing leakage into the retina and macular oedema resulting in vision loss. It is much less common in anterior uveitis or in patients with intraocular lymphoma who may have marked signs of intraocular inflammation. New drugs used for chemotherapy (cytarabine, immune checkpoint inhibitors, BRAF inhibitors, EGFR inhibitors, bispecific anti-EGFR inhibitors, MET receptor inhibitors and Bruton tyrosine kinase inhibitors) can also cause different types of uveitis and BRB disruption. As malignant disease itself can cause uveitis, particularly from breast, lung and gastrointestinal tract cancers, it can be clinically difficult to sort out the cause of BRB disruption. Immunosuppression due to malignant disease and/or chemotherapy can lead to infection which can also cause BRB disruption and intraocular infection. In this paper we address the pathophysiology of BRB disruption related to intraocular inflammation and malignancy, methods for estimating the extent and effect of the disruption and examine why some types of intraocular inflammation and malignancy cause BRB disruption and others do not. Understanding this may help sort and manage these patients, as well as devise future therapeutic approaches.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Tomkins-Netzer O, Niederer R, Greenwood J, et al. Mechanisms of blood-retinal barrier disruption related to intraocular inflammation and malignancy. Prog Retin Eye Res. 2024. PMID: 38242492. doi:10.1016/j.preteyeres.2024.101245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。